Eli Lilly ($LLY) has nabbed a win in the first U.S. trial over claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta. With more trials on the way--and thousands of cases alleging that the drugmaker soft-pedaled on the drug's withdrawal symptoms--the early victory could score the Indianapolis drugmaker some leverage. More